Sclerotherapy treatment of XXXX : a large single-centre experience.

@entity2694 @entity1 @entity13420
BACKGROUND: Percutaneous sclerotherapy is an alternative to surgery for the treatment of @entity2694 (LMs). We present a large series of @entity1 undergoing sclerotherapy for macrocystic LMs with detailed visual acuity (VA) outcome data. METHODS: Data were collected prospectively in all @entity1 with macrocystic orbital LMs undergoing sclerotherapy. Sclerotherapy was performed under general anaesthesia, instilling @entity13420 under imaging control. Procedures were repeated at 2-week to 6-week intervals, depending on clinical response. @entity1 underwent ophthalmological assessment, ultrasound and/or MRI before and after treatment. PRIMARY OUTCOME MEASURE: change in maximal radiological diameter of the LM. Secondary outcome measure: change in VA after treatment. RESULTS: 29 @entity1 underwent 71 procedures (1-8 procedures per @entity1 ) over 6.7   years. Mean age=7.31   years. 11 @entity1 (37.9%) had undergone previous treatment, including excision biopsy, drainage and decompression. All @entity1 presented with proptosis and/or pseudoptosis. 23 @entity1 (79.3%) had decreased VA at presentation. Average follow-up was 21.8   months (range 3-75   months). All @entity1 achieved a reduction in maximal lesion diameter of >= 50%, with complete radiological resolution in 51.7% (n=15). VA improved in 18/23 @entity1 (78.2%). Average logMAR before treatment=0.43 (SD   0.47); average after treatment=0.25 (SD   0.32); p<0.01. There was one complication (1.4%): one @entity1 required a lateral canthotomy for an intralesional haematoma 2   h after sclerotherapy. CONCLUSIONS: Sclerotherapy is a safe and highly effective treatment for orbital LMs with excellent VA outcomes. It should be considered as the first-line treatment for this condition.
